


UNIVERSITY OF HELSINKI FACULTY OF MEDICINE

Vaativa laskeumakirurgia – mitä sanoo EBM?

Tomi Mikkola

HYKS Naistenklinikka

Lifetime risk of POP surgery



- In 2007-11 evaluated 10,177,480 US women
 - 57,755 POP surgeries by age 80 lifetime risk 12.6%

Recurrent rates after POP surgery

- With native tissue repair approximately 30%
 - anterior compartment up to 50-60%
 - Level I (apical) defect in 60%
- Native tissue repair results poor
 - improve native tissue repair not in the past 100yrs
 - use of mesh particularly in recurrent POP
- Rational of using mesh
 - abdominal hernia repairs
 - mesh standard of care in hernia repair
 - long development of material/methods

Olsen et al. Obstet Gynecol 1997 DeLancey et al. 2006 Amato et al. Cochrane 2009

Mesh in POP surgery

- First vaginal mesh for POP surgery approved by FDA in 2002
 - rapid increase in use after 2005
 - also laparoscopic/robotic techniques evolved
 - by 2009 surpassed the abdominal approach
- Flaws in the initiation of vaginal mesh surgery
 - no routine follow-up/ report of adverse events
 - industry driven training/marketing of "simple kits"
 - "in my hands" one center publications

FDA warnings


Serious Complications Associated with Transvaginal Placement of Surgical Mesh for Pelvic Organ Prolapse: FDA Safety Communication

"erosion of mesh through the vagina is the most common and consistently reported mesh-related complication from transvaginal POP surgeries using" "Both mesh erosion and mesh contraction may lead to severe pelvic pain"

FDA 2008 and 2011

- Systematic review of complications
 - wound granulation 8%
 - erosion 10%
 - dyspareunia 9%

FDA warnings



Skoczylas et al. Int J Urogynecol 2014

Where are we today?

- Positive aspects
 - studies required prior to introducing new products
 - development of products less mesh, apical support, etc.
 - evaluation of subjective results
 - more multicenter large scale studies (?)
 - centralization of mesh surgery started
 - hopefully less "wannabe" POP-surgeons
 - discussion/recommendations about skills and volume
 - more critical in patient selection
 - mainly in recurrent POP


Where are we today?

- Negative aspects
 - in some countries mesh use completely stopped
 - results of native tissue repair remain poor
 - seeking arguments to not use mesh hardly improves patient care
 - "hostile" debate about the rational of using vaginal vs. laparoscopic/robotic mesh (or no mesh)
 - instead we need objective data
 - patients who require mesh for POP are afraid
- More importantly where should we go?

Key questions


- Should we discard vaginal mesh in POP surgery?
 - back to native tissue repair?
- Should we use mainly laparoscopic/robotic approach?
 - do we have data?
- What type of mesh to use?
 - current development/understanding?
- Patient/surgeon selection?
 - risk factors?

Native tissue repair vs. mesh



- 202 women anterior colporraphy vs. tailored mesh
 - in 3 year follow-up failure if POP-Q Aa/Ba stage II

Laparoscopic/robotic approach?



- Only one randomized study LSC vs. TVM
 - 1 erosion in LSC vs. 5 in TVM
 - satisfaction 87% in LSC vs. 79% in TVM
 - operating time 97min in LSC vs. 50min in TVM
 - LSC better? in hands of an expert laparoscopist
- Robot in POP surgery expensive "toys for the boys"

Maher et al. Am J Obstet Gynecol 2011 Paraiso et al. Obstet Gynecol 2011

What type of mesh to use?

- Type I macroporous (pore size > 75µm)
- Vaginal mesh retraction correlates with pain
 - is it contraction/shrinkage or folding?
 - also partially behind erosions?
- Mesh size!
- Apical support!

Mesh/patient/surgeon selection

- Prolift[®] vaginal mesh (n=294)
 - anterior 71 (24%)
 - posterior 110 (37%)
 - anterior and posterior/ total 113 (38%)
- Independent risk factors for mesh exposure (12%)
 - smoking OR 3.1 (1.1 8.7)
 - total mesh OR 3.0 (1.2 7.0)
 - Surgeons experience OR 0.5 (0.3 0.8) per 10yrs

Nordic TVM Group


- 12 month RCT colporraphy (n=189) vs. Prolift[®] anterior (n=200)
- POP-Q stage 0-1 and symptomless
 - colporraphy 35% vs. TVM 61% (p< 0.001)</p>
- Erosion needing surgical revision
 - colporraphy 0 vs. TVM 6 (3%) (p< 0.03)</p>


Importance of apical support

POP surgery 1999 (n=3244)	Re-operation after 10 years
Anterior colporraphy	20%
Anterior colporraphy and apical support	11% (p< 0.01)
Posterior colporraphy	15%
Posterior colporraphy and apical support	10%

Advanced vaginal approach

- Smaller vaginal mesh with apical support
 - Uphold[®] after dissection the suturing device is used to pull the mesh through the sacrospinous ligament, medial to the ischial spine





- Preliminary data from one center/surgeon
 - median follow-up 12 (0.4–30.9) months promising anatomical and QoL results
 - erosion 2.6 %

Nordic TVM Group

- Prospective, multicenter (24 clinics Sweden, Norway, Denmark, Finland), open-label, single cohort feasibility study of Uphold LITE[®]
- Inclusion primary or recurrent ≥ stage 2 prolapse of the middle compartment (vaginal/uterine) with or without cystocele
- Primary outcome complications
- Secondary outcome anatomy and symptoms

Conclusions

- Native tissue repair results poor – particularly in anterior/apical defects
- Mesh in recurrent POP surgery is needed
- Laparoscopic sacrocolpopexy is an option – particularly in posterior/apical defects
- In vaginal approach small/light mesh with apical support

Conclusions

• The use of mesh in pelvic reconstructive surgery need to be centralized

– sufficient volumes/skills

- More high quality multicenter studies needed
 - the ideal method in POP surgery remains to be developed

Clinical approach

- Good diagnostic and native tissue repair skills
 - colpocleisis and sacrospinous fixation should not be forgotten
- Mesh mainly in recurrent POP surgery
 - apical support crucial
- Both vaginal and laparoscopic methods should be used
 - vaginal mesh mainly in anterior/apical defects
 - laparoscopic mesh mainly in posterior/apical defects